News By Tag
News By Location
Global Inflammatory Bowel Diseases (Ibd) Drug Market Forecast 2018-2028
There appear to be a marked variation in the prevalence rates of IBD. Crohn's disease and ulcerative colitis are much more common in developed countries than developing ones. One of the explanations is that there may be one or more environmental factors that increase the risk of IBD, which are presumably associated with Western diets and other lifestyle factors. The incidence rate of IBD appears to have stabilised in the West. In developing countries however, the number of new cases is growing annually. This may be due to Westernisation, changes in hygiene practices or more awareness of the disease. In any case, it seems likely that incidence and prevalence of IBD will increase in many countries around the world. As a consequence, demand for IBD drugs will rise (https://www.visiongain.com/
The lead analyst of the report commented "The inflammatory bowel diseases (IBD) drugs market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis. The IBD therapies market contains a diverse range of drugs, including biologics, which stimulate its revenue value and expand the market. Also, the incidence of IBD in emerging national markets is expected to rise as those countries become more developed."
Leading companies featured in the report include AbbVie, Janssen, Allergan, Shire, Takeda, Johnson & Johnson, UCB, Valeant, Astellas, Celgene, Takeda.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@